| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 94.11K | 1.21M | 1.69M | 1.05M | 2.91M | 1.72M | 1.51M | 6.19M | 1.7M | 10.12M |
| Revenue Growth % | - | 11.88% | 0.4% | -0.38% | 1.78% | -0.41% | -0.12% | 3.11% | -0.73% | 4.96% |
| Cost of Goods Sold | 0 | 478K | 1.01M | 48.3M | 105.42M | 134.89M | 0 | 0 | 0 | 141.02M |
| COGS % of Revenue | - | 0.39% | 0.6% | 46.2% | 36.25% | 78.65% | - | - | - | 13.93% |
| Gross Profit | 94.11K | 734K | 684K | -47.25M | -102.51M | -133.17M | 1.51M | 6.19M | 1.7M | -130.9M |
| Gross Margin % | 1% | 0.61% | 0.4% | -45.2% | -35.25% | -77.65% | 1% | 1% | 1% | -12.93% |
| Gross Profit Growth % | - | 6.8% | -0.07% | -70.08% | -1.17% | -0.3% | 1.01% | 3.11% | -0.73% | -78.09% |
| Operating Expenses | 8.2M | 15.59M | 25.11M | 41.48M | 145.07M | 169.96M | 141.88M | 149.09M | 181.4M | 110.53M |
| OpEx % of Revenue | 87.14% | 12.86% | 14.83% | 39.68% | 49.89% | 99.1% | 94.15% | 24.07% | 106.83% | 10.92% |
| Selling, General & Admin | 6.04M | 5.15M | 9.1M | 16.85M | 39.45M | 34.97M | 31.86M | 31.9M | 46.74M | 0 |
| SG&A % of Revenue | 64.22% | 4.25% | 5.37% | 16.12% | 13.57% | 20.39% | 21.14% | 5.15% | 27.53% | - |
| Research & Development | 2.17M | 10.44M | 16.01M | 24.64M | 105.62M | 134.99M | 110.84M | 117.35M | 130.48M | 158.14M |
| R&D % of Revenue | 23.09% | 8.61% | 9.46% | 23.57% | 36.32% | 78.71% | 73.55% | 18.95% | 76.84% | 15.63% |
| Other Operating Expenses | 0 | -26K | -46K | 3.97M | 0 | 0 | -823K | -166K | 4.17M | -47.61M |
| Operating Income | -8.11M | -14.38M | -23.42M | -57.53M | -247.58M | -303.13M | -140.37M | -142.89M | -179.7M | -241.43M |
| Operating Margin % | -86.14% | -11.86% | -13.83% | -55.04% | -85.14% | -176.75% | -93.15% | -23.07% | -105.83% | -23.86% |
| Operating Income Growth % | - | -0.77% | -0.63% | -1.46% | -3.3% | -0.22% | 0.54% | -0.02% | -0.26% | -0.34% |
| EBITDA | -4.47M | -13.9M | -22.41M | -55.82M | -243.02M | -297.57M | -131.92M | -135.47M | -173.14M | -233.71M |
| EBITDA Margin % | -47.5% | -11.47% | -13.24% | -53.4% | -83.57% | -173.51% | -87.54% | -21.87% | -101.96% | -23.09% |
| EBITDA Growth % | - | -2.11% | -0.61% | -1.49% | -3.35% | -0.22% | 0.56% | -0.03% | -0.28% | -0.35% |
| D&A (Non-Cash Add-back) | 3.64M | 478K | 1.01M | 1.71M | 4.56M | 5.57M | 8.46M | 7.42M | 6.57M | 7.72M |
| EBIT | -8.11M | -14.38M | -23.42M | -52.03M | -141.96M | -168.15M | -140.93M | -139.66M | -163.34M | -240.79M |
| Net Interest Income | 0 | 75K | 84K | 4.11M | 2.54M | 536K | -843K | -7.2M | -31.56M | 23.06M |
| Interest Income | 7.93K | 75K | 84K | 4.12M | 2.54M | 536K | 262K | 1.71M | 13.51M | 32.35M |
| Interest Expense | 0 | 0 | 0 | 12.67K | 0 | 0 | 1.1M | 8.9M | 45.07M | 9.29M |
| Other Income/Expense | 7.93K | 49K | 38K | 6.91M | 138.89M | 136.88M | -1.66M | -5.67M | -28.7M | 22.29M |
| Pretax Income | -8.1M | -14.33M | -23.38M | -36.33M | -108.69M | -166.26M | -142.04M | -148.57M | -208.4M | -219.13M |
| Pretax Margin % | -86.05% | -11.82% | -13.81% | -34.75% | -37.38% | -96.94% | -94.25% | -23.99% | -122.73% | -21.65% |
| Income Tax | -634.51K | -1.78M | -3.65M | -5.21M | 15.16M | -24.16M | 58K | 272K | -19K | 1.53M |
| Effective Tax Rate % | 0.92% | 0.88% | 0.84% | 0.86% | 1.14% | 0.85% | 1% | 1% | 1% | 1.01% |
| Net Income | -7.46M | -12.55M | -19.73M | -31.11M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M |
| Net Margin % | -79.31% | -10.35% | -11.65% | -29.76% | -42.59% | -82.85% | -94.29% | -24.03% | -122.72% | -21.8% |
| Net Income Growth % | - | -0.68% | -0.57% | -0.58% | -2.98% | -0.15% | -0% | -0.05% | -0.4% | -0.06% |
| Net Income (Continuing) | -7.46M | -12.55M | -19.73M | -44.75M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.54 | -0.91 | -1.43 | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.87 |
| EPS Growth % | - | -0.69% | -0.57% | 0.31% | -1.91% | 0.04% | 0.29% | 0.2% | 0.24% | 0.28% |
| EPS (Basic) | -0.54 | -0.91 | -1.43 | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.87 |
| Diluted Shares Outstanding | 13.78M | 13.78M | 13.78M | 31.56M | 43.07M | 51.56M | 72.08M | 94.99M | 173.94M | 255.16M |
| Basic Shares Outstanding | 13.78M | 13.78M | 13.78M | 31.56M | 43.07M | 51.56M | 72.08M | 94.99M | 173.94M | 255.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 11.49M | 30.93M | 142.48M | 199.14M | 249.26M | 193.98M | 346.95M | 425.77M | 275.3M | 660.93M |
| Cash & Short-Term Investments | 10.18M | 28.06M | 137.07M | 189.3M | 211.43M | 154.09M | 310.34M | 382.44M | 239.57M | 588.02M |
| Cash Only | 10.18M | 28.06M | 137.07M | 189.3M | 211.43M | 154.09M | 310.34M | 382.44M | 239.57M | 227.38M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 360.64M |
| Accounts Receivable | 0 | 2.18M | 4.73M | 9.26M | 30.52M | 29.68M | 68K | 28.98M | 1.05M | 48.24M |
| Days Sales Outstanding | - | 656.22 | 1.02K | 3.23K | 3.83K | 6.32K | 16.47 | 1.71K | 225.06 | 1.74K |
| Inventory | 0 | 0 | 0 | 2.21M | 0 | 0 | 0 | 0 | 0 | 4.14M |
| Days Inventory Outstanding | - | - | - | 16.69 | - | - | - | - | - | 10.71 |
| Other Current Assets | 1.15M | 0 | 0 | 717K | 279K | 0 | 27.83M | 2.02M | 26.05M | 5.32M |
| Total Non-Current Assets | 11.16M | 3.25M | 6.18M | 18.51M | 54.28M | 100.26M | 58.61M | 64.5M | 100.08M | 121.8M |
| Property, Plant & Equipment | 915.95K | 3.25M | 6.18M | 9.22M | 51.57M | 89.68M | 52.32M | 58.42M | 95.65M | 105.05M |
| Fixed Asset Turnover | 0.10x | 0.37x | 0.27x | 0.11x | 0.06x | 0.02x | 0.03x | 0.11x | 0.02x | 0.10x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 10.24M | 9.5M | 0 | 9.29M | 254K | 158K | 65K | 0 | 0 | 12.37M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | -9.5M | 0 | 0 | 2.04M | 8.67M | 6.23M | 4.01M | 1.36M | 1.13M |
| Total Assets | 22.66M | 34.18M | 148.66M | 217.66M | 303.53M | 294.24M | 405.56M | 490.27M | 375.38M | 782.73M |
| Asset Turnover | 0.00x | 0.04x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.01x | 0.00x | 0.01x |
| Asset Growth % | - | 0.51% | 3.35% | 0.46% | 0.39% | -0.03% | 0.38% | 0.21% | -0.23% | 1.09% |
| Total Current Liabilities | 1.95M | 2.73M | 5.03M | 12.52M | 24.98M | 33.63M | 28.55M | 46.37M | 44.74M | 60.74M |
| Accounts Payable | 1.69M | 1.44M | 1.95M | 3.04M | 0 | 2.26M | 431K | 531K | 103K | 1.97M |
| Days Payables Outstanding | - | 1.1K | 703.95 | 22.94 | - | 6.12 | - | - | - | 5.1 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 2.51M | 3.59M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 53K | 197K | 569K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 259.41K | 1.3M | 589K | 11.03M | 15.51M | 19.05M | 160K | 10.57M | 15.29M | 23.66M |
| Current Ratio | 5.90x | 11.31x | 28.31x | 15.91x | 9.98x | 5.77x | 12.15x | 9.18x | 6.15x | 10.88x |
| Quick Ratio | 5.90x | 11.31x | 28.31x | 15.73x | 9.98x | 5.77x | 12.15x | 9.18x | 6.15x | 10.81x |
| Cash Conversion Cycle | - | - | - | 3.23K | - | - | - | - | - | 1.75K |
| Total Non-Current Liabilities | 0 | 758K | 1.03M | 601K | 23.71M | 50.57M | 63.69M | 145.23M | 219.17M | 294.66M |
| Long-Term Debt | 0 | 0 | 0 | 221K | 0 | 0 | 47.02M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 188K | 265K | 221K | 23.71M | 50.57M | 16.55M | 19.22M | 47.91M | 49.63M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 570K | 763K | 159K | 0 | 0 | 128K | 126.02M | 171.26M | 245.03M |
| Total Liabilities | 1.95M | 3.49M | 6.06M | 12.52M | 48.69M | 84.2M | 92.24M | 191.6M | 263.91M | 355.4M |
| Total Debt | 0 | 188K | 265K | 221K | 26.22M | 54.16M | 68.01M | 24.26M | 52.97M | 52.63M |
| Net Debt | -10.18M | -27.87M | -136.81M | -189.08M | -185.21M | -99.92M | -242.32M | -358.18M | -186.6M | -174.75M |
| Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -4541.96x | - | - | -127.04x | -16.05x | -3.99x | -25.98x |
| Total Equity | 20.71M | 30.69M | 142.6M | 205.14M | 254.84M | 210.03M | 313.32M | 298.67M | 111.47M | 427.32M |
| Equity Growth % | - | 0.48% | 3.65% | 0.44% | 0.24% | -0.18% | 0.49% | -0.05% | -0.63% | 2.83% |
| Book Value per Share | 1.50 | 2.23 | 10.35 | 6.50 | 5.92 | 4.07 | 4.35 | 3.14 | 0.64 | 1.67 |
| Total Shareholders' Equity | 20.71M | 30.69M | 142.6M | 205.14M | 254.84M | 210.03M | 313.32M | 298.67M | 111.47M | 427.32M |
| Common Stock | 322 | 577 | 1K | 1.28K | 120K | 121K | 4K | 8K | 8K | 12K |
| Retained Earnings | -9.33M | -28.18M | -47.9M | 163.84M | -237.15M | -379.24M | -521.34M | -670.18M | -878.56M | -1.1B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -4.65M | -3.85M | -76.27M | -8.69M | -5.86M | -8.45M | -38.9M | -28.99M | -29.17M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.33M | -9.85M | -16.36M | -25.85M | -101.48M | -117.76M | -117.86M | -112.31M | -145.59M | -206.27M |
| Operating CF Margin % | -35.34% | -8.13% | -9.66% | -24.73% | -34.9% | -68.66% | -78.21% | -18.13% | -85.74% | -20.38% |
| Operating CF Growth % | - | -1.96% | -0.66% | -0.58% | -2.93% | -0.16% | -0% | 0.05% | -0.3% | -0.42% |
| Net Income | -7.46M | -12.55M | -19.73M | -31.11M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M |
| Depreciation & Amortization | 3.64M | 478K | 1.01M | 1.1M | 4.61M | 5.66M | 8.46M | 7.42M | 6.57M | 7.72M |
| Stock-Based Compensation | 0 | 2.26M | 3.15M | 5.03M | 30.21M | 20.11M | 9.94M | 12.01M | 11.2M | 15.47M |
| Deferred Taxes | 0 | 0 | 0 | -5.21M | -399K | -1.34M | -72K | -268K | -986K | -185K |
| Other Non-Cash Items | 916.23K | 1.2M | 5.17M | -1.07M | 4.14M | -1.5M | 1.77M | 13.39M | 45.72M | 15.04M |
| Working Capital Changes | -413.95K | -1.23M | -795K | 5.42M | -16.2M | 1.41M | 4.14M | 3.97M | 292K | -23.66M |
| Change in Receivables | -413.95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.23M |
| Change in Payables | 0 | 507K | 434K | 8.65M | -1.45M | 1.44M | -1.82M | 22K | -509K | 1.59M |
| Cash from Investing | -754.14K | -1.85M | -2.88M | -7.65M | -18.67M | -14.68M | -8.86M | -10.84M | -10.99M | -394.55M |
| Capital Expenditures | -762.07K | -1.85M | -2.88M | -8.77M | -18.34M | -14.68M | -8.86M | -10.84M | -10.99M | -22.07M |
| CapEx % of Revenue | 8.1% | 1.53% | 1.7% | 8.39% | 6.31% | 8.56% | 5.88% | 1.75% | 6.47% | 2.18% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 7.92K | 0 | 0 | 1.13M | -327K | 0 | 0 | 0 | 0 | -12.74M |
| Cash from Financing | 12.23M | 32.22M | 127.69M | 117.49M | 108.86M | 74.42M | 284.06M | 223.61M | -883K | 589.55M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 12.23M | 0 | 0 | 0 | -115.92M | -79.75M | 38.16M | 59.76M | -883K | 39.58M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.09M | -11.7M | -19.24M | -34.62M | -120.15M | -132.44M | -126.72M | -123.15M | -156.57M | -241.09M |
| FCF Margin % | -43.43% | -9.66% | -11.36% | -33.12% | -41.32% | -77.22% | -84.09% | -19.88% | -92.21% | -23.82% |
| FCF Growth % | - | -1.86% | -0.64% | -0.8% | -2.47% | -0.1% | 0.04% | 0.03% | -0.27% | -0.54% |
| FCF per Share | -0.30 | -0.85 | -1.40 | -1.10 | -2.79 | -2.57 | -1.76 | -1.30 | -0.90 | -0.94 |
| FCF Conversion (FCF/Net Income) | 0.45x | 0.78x | 0.83x | 0.83x | 0.82x | 0.83x | 0.83x | 0.75x | 0.70x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1.53M | 1.84M | 364K | 471K | 551K | 2.39M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -36.05% | -48.84% | -22.77% | -17.9% | -53.85% | -61.13% | -54.3% | -48.64% | -101.61% | -81.91% |
| Return on Invested Capital (ROIC) | -57.78% | -161.66% | -407.88% | -394.78% | -433.37% | -252.98% | -116.27% | -1865.44% | - | -204.08% |
| Gross Margin | 100% | 60.56% | 40.4% | -4520.4% | -3525.1% | -7765.19% | 100% | 100% | 100% | -1293.48% |
| Net Margin | -7931.14% | -1035.48% | -1165.21% | -2976.49% | -4258.91% | -8285.36% | -9429.06% | -2402.95% | -12272.26% | -2180.45% |
| Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x |
| Interest Coverage | - | - | - | -4541.96x | - | - | -127.04x | -16.05x | -3.99x | -25.98x |
| FCF Conversion | 0.45x | 0.78x | 0.83x | 0.83x | 0.82x | 0.83x | 0.83x | 0.75x | 0.70x | 0.93x |
| Revenue Growth | - | 1187.83% | 39.69% | -38.26% | 178.19% | -41.02% | -12.13% | 311.02% | -72.59% | 496% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| License | 242K | 1.51M | 6.19M | 1.7M | 10.12M |
| License Growth | - | 522.73% | 311.02% | -72.59% | 496.00% |
| Grant | 1.47M | 823K | 166K | - | - |
| Grant Growth | - | -44.13% | -79.83% | - | - |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Europe | - | - | - | - | 10.12M |
| Europe Growth | - | - | - | - | - |
| UNITED STATES | - | 1.51M | 6.19M | 1.35M | - |
| UNITED STATES Growth | - | - | 311.02% | -78.17% | - |
Autolus Therapeutics plc (AUTL) reported $51.1M in revenue for fiscal year 2024. This represents a 54227% increase from $0.1M in 2015.
Autolus Therapeutics plc (AUTL) grew revenue by 496.0% over the past year. This is strong growth.
Autolus Therapeutics plc (AUTL) reported a net loss of $224.8M for fiscal year 2024.
Autolus Therapeutics plc (AUTL) has a return on equity (ROE) of -81.9%. Negative ROE indicates the company is unprofitable.
Autolus Therapeutics plc (AUTL) had negative free cash flow of $278.0M in fiscal year 2024, likely due to heavy capital investments.